Sciele Pharma, Inc. Announces That Addrenex Pharmaceuticals Initiates Phase II Clinical Trial of ADX415 for the Treatment of Hypertension

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc., a Shionogi Company, today announced that Addrenex Pharmaceuticals, Inc. has initiated its Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist, specific to Alpha-2 receptors.